Related Experiment Video
Updated: Nov 6, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.7K
Abstract:
Increasingly, oncologists are turning to tumor mutation burden (TMB) as a biomarker of response to immune checkpoint inhibitors. However, recent research suggests that TMB needs to be further refined before it can be adopted broadly across tumor types and patient populations.
Insights
Tumor mutation burden (TMB) shows promise as a biomarker for predicting responses to immune checkpoint inhibitors. Further research is needed to refine TMB for widespread use across diverse cancers and patient groups.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment.
- Tumor mutation burden (TMB) is emerging as a predictive biomarker for ICI response.
- Current TMB assays require standardization for broad clinical application.
Discussion:
- TMB reflects the number of mutations within a tumor's genome.
- Higher TMB may correlate with increased neoantigen presentation, enhancing immune recognition.
- Factors like tumor type, sequencing methods, and analytical pipelines influence TMB values.
Key Insights:
- TMB is a valuable but imperfect biomarker for ICI therapy.
- Refining TMB measurement and interpretation is crucial for clinical utility.
- Standardization across different platforms and tumor types is essential.
Outlook:
- Further research will focus on harmonizing TMB assessment methodologies.
- Development of more robust TMB signatures will improve patient stratification.
- Optimized TMB biomarkers will enhance the efficacy and accessibility of immunotherapy.
